Overall, these results showed that cell lines with SCS interaction sets for BRAF/MAPK inhibitors were significantly enriched with tissues originating from the skin (59.2%, all melanoma) and large intestine (18.4%, all colorectal cancer). The gene discussed is BRAF; the disease is melanoma.